Tourette Syndrome (TS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Tourette
Syndrome (TS) Market Outlook
Thelansis’s “Tourette Syndrome
(TS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2026 To 2036” covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Tourette
Syndrome (TS) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Tourette
Syndrome (TS) Overview
Tourette syndrome (TS) is a
childhood-onset neurodevelopmental disorder characterized by chronic,
fluctuating motor and vocal tics, driven by dopaminergic pathway dysregulation
within cortico-striato-thalamo-cortical brain circuits. Diagnosis is established
clinically under DSM-5 criteria, requiring multiple motor tics and at least one
vocal tic with onset before age 18, persisting for greater than one year. Tics
are preceded by a premonitory urge that is temporarily relieved by execution.
First-line management centers on non-pharmacological behavioral therapy,
primarily Comprehensive Behavioral Intervention for Tics (CBIT), alongside
psychoeducation and school accommodations. For severe tics, alpha-2 agonists,
dopamine antagonists, or off-label VMAT2 inhibitors like tetrabenazine are
utilized. In 2026, the selective D1 antagonist ecopipam remains a prominent
investigational agent showing promising data. Prognosis is generally favorable,
with many patients experiencing adult remission, though psychiatric comorbidities
often persist.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment